You are here

AstraZeneca

AstraZeneca, after prior issues with FluMist, ramps up production in response to pandemic

AstraZeneca, after prior issues with FluMist, ramps up production in response to pandemic

Fierce Pharma

Flag link:

AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine doses: report

AstraZeneca will work with Mexico, Argentina to produce COVID-19 vaccine doses: report

Fierce Pharma

Flag link:

AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

Fierce Pharma

Flag link:

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Pharmaceutical Business Review

patritumab deruxtecan

non-small cell lung cancer

clinical trials

Flag link:

AstraZeneca in first COVID-19 vaccine deal with Chinese company

AstraZeneca in first COVID-19 vaccine deal with Chinese company

Reuters

Shenzhen Kangtai Biological

Flag link:

Redx shares soar after IPF drug license deal with AstraZeneca

Redx shares soar after IPF drug license deal with AstraZeneca

Pharmaforum

Flag link:

5 Coronavirus Vaccines With Huge Operation Warp Speed Deals

5 Coronavirus Vaccines With Huge Operation Warp Speed Deals

Motley Fool

Operation Warp Speed

Moderna Therapeutics

Flag link:

Astra shakes things up with Covid-19 pricing disclosure

Astra shakes things up with Covid-19 pricing disclosure

EP Vantage

Flag link:

AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio

AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio

Yahoo/Benzinga

Flag link:

After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment

After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment

Endpoints

clinical trials

chronic kidney disease

Flag link:

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront

Motley Fool

Flag link:

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo

Pharmaforum

Flag link:

AstraZeneca pledges $174M to ramp up coronavirus vaccine supply deal with Emergent

AstraZeneca pledges $174M to ramp up coronavirus vaccine supply deal with Emergent

Fierce Pharma

Emergent BioSolutions

University of Oxford

Flag link:

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?

Motley Fool

Moderna Therapeutics

Flag link:

Why AstraZeneca Shares Slumped This Week Despite Positive Vaccine News

Why AstraZeneca Shares Slumped This Week Despite Positive Vaccine News

Motley Fool

University of Oxford

Flag link:

Cut-price drug venture takes aim at Pfizer and Astrazeneca

Cut-price drug venture takes aim at Pfizer and Astrazeneca

EP Vantage

Flag link:

AstraZeneca COPD drug finally gets OK from FDA, inching closer to GSK leader

AstraZeneca COPD drug finally gets OK from FDA, inching closer to GSK leader

Endpoints

Breztri Aerosphere

Flag link:

Oxford Cautious About Timeline Following COVID-19 Vaccine Data

Oxford Cautious About Timeline Following COVID-19 Vaccine Data

BioSpace

University of Oxford

Flag link:

Pharma promises lawmakers, again and again, industry won’t cut corners with Covid-19 vaccines

Pharma promises lawmakers, again and again, industry won’t cut corners with Covid-19 vaccines

Stat

Moderna Therapeutics

Flag link:

Top analyst pokes hole in AstraZeneca/Oxford data while scientists tamper hope for fast rollout

Top analyst pokes hole in AstraZeneca/Oxford data while scientists tamper hope for fast rollout

Endpoints

University of Oxford

clinical trials

Moderna Therapeutics

Flag link:

Pages